Genedrive PLC
LSE:GDR
Intrinsic Value
Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. [ Read More ]
The intrinsic value of one GDR stock under the Base Case scenario is 0.209 GBX. Compared to the current market price of 3.375 GBX, Genedrive PLC is Overvalued by 94%.
Valuation Backtest
Genedrive PLC
Run backtest to discover the historical profit from buying and selling GDR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Genedrive PLC's business.
What risks and challenges
does Genedrive PLC face in the near future?
Summarize the latest earnings report
of Genedrive PLC.
Provide P/E
for Genedrive PLC and its competitors.
Balance Sheet Decomposition
Genedrive PLC
Current Assets | 4.1m |
Cash & Short-Term Investments | 2.6m |
Receivables | 989k |
Other Current Assets | 525k |
Non-Current Assets | 392k |
PP&E | 392k |
Current Liabilities | 2.4m |
Accounts Payable | 935k |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 19k |
Long-Term Debt | 19k |
Earnings Waterfall
Genedrive PLC
Revenue
|
55k
GBP
|
Operating Expenses
|
-5.3m
GBP
|
Operating Income
|
-5.2m
GBP
|
Other Expenses
|
74k
GBP
|
Net Income
|
-5.2m
GBP
|
Free Cash Flow Analysis
Genedrive PLC
What is Free Cash Flow?
GDR Profitability Score
Profitability Due Diligence
Genedrive PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Genedrive PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
GDR Solvency Score
Solvency Due Diligence
Genedrive PLC's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Genedrive PLC's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GDR Price Targets Summary
Genedrive PLC
Shareholder Return
GDR Price
Genedrive PLC
Average Annual Return | 5.98% |
Standard Deviation of Annual Returns | 78.08% |
Max Drawdown | -99% |
Market Capitalization | 4.5m GBX |
Shares Outstanding | 134 351 008 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.
Contact
IPO
Employees
Officers
The intrinsic value of one GDR stock under the Base Case scenario is 0.209 GBX.
Compared to the current market price of 3.375 GBX, Genedrive PLC is Overvalued by 94%.